Idexx Laboratories Stock Cash Flow From Operations
| IX1 Stock | EUR 410.30 26.50 6.07% |
IDEXX Laboratories fundamentals help investors to digest information that contributes to IDEXX Laboratories' financial success or failures. It also enables traders to predict the movement of IDEXX Stock. The fundamental analysis module provides a way to measure IDEXX Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IDEXX Laboratories stock.
IDEXX |
IDEXX Laboratories Company Cash Flow From Operations Analysis
IDEXX Laboratories' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current IDEXX Laboratories Cash Flow From Operations | 542.98 M |
Most of IDEXX Laboratories' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IDEXX Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, IDEXX Laboratories has 542.98 M in Cash Flow From Operations. This is 2.98% higher than that of the Healthcare sector and 136.49% higher than that of the Diagnostics & Research industry. The cash flow from operations for all Germany stocks is 44.09% higher than that of the company.
IDEXX Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IDEXX Laboratories' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IDEXX Laboratories could also be used in its relative valuation, which is a method of valuing IDEXX Laboratories by comparing valuation metrics of similar companies.IDEXX Laboratories is currently under evaluation in cash flow from operations category among its peers.
IDEXX Fundamentals
| Return On Equity | 1.05 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 35.12 B | |||
| Shares Outstanding | 82.9 M | |||
| Shares Owned By Insiders | 0.39 % | |||
| Shares Owned By Institutions | 92.77 % | |||
| Price To Earning | 57.45 X | |||
| Price To Book | 75.09 X | |||
| Price To Sales | 9.95 X | |||
| Revenue | 3.37 B | |||
| Gross Profit | 2 B | |||
| EBITDA | 1.01 B | |||
| Net Income | 679.09 M | |||
| Cash And Equivalents | 116.62 M | |||
| Cash Per Share | 1.36 X | |||
| Total Debt | 694.39 M | |||
| Current Ratio | 1.01 X | |||
| Book Value Per Share | 7.34 X | |||
| Cash Flow From Operations | 542.98 M | |||
| Earnings Per Share | 7.59 X | |||
| Price To Earnings To Growth | 7.23 X | |||
| Target Price | 707.0 | |||
| Number Of Employees | 10.78 K | |||
| Beta | 1.17 | |||
| Market Capitalization | 37.22 B | |||
| Total Asset | 2.75 B | |||
| Z Score | 32.8 | |||
| Net Asset | 2.75 B |
About IDEXX Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IDEXX Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IDEXX Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IDEXX Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in IDEXX Stock
When determining whether IDEXX Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IDEXX Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Idexx Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Idexx Laboratories Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.